Authors


Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences

Latest:

Saving the world: Pharmaceutical innovation in nine months

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.


Jean-Francois Korobelnik, MD

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Jennifer Lim, MD, FARVO, FASRS

Latest:

Patient Cases Demonstrating the Application of Treat and Extend Algorithm for Faricimab in DME

Dr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.


George Magrath, MD

Latest:

Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disorders

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.


Laird Harrison

Latest:

Microaneurysm turnover predicts diabetic retinopathy progression

Micoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.



Professor William Ayliffe

Latest:

Electroretinography: Out of the laboratory and into the clinic

OCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.


Julianne Mobilian

Latest:

ASRS 2019 Street Team: W. Lloyd Clark, MD

ICYMI: Dr. Clark breaks down the results of the PANORAMA Study


Dr David Gaucher

Latest:

Diagnosing early-stage AMD with a dark adaptation device

A dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.


Steve Lenier

Latest:

Applying AI in fundus images

FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR


Kamal Kishore, MD

Latest:

Nailing intravitreal implant injections

Treating diabetic macular edema (DME) has evolved from the ETDRS-style focal/grid laser being the standard of care since 1985 to the modern era of pharmacotherapy-with anti-vascular endothelial growth factor (VEGF) injections now taking center stage as primary treatment for most patients.


Adam Berger, MD

Latest:

Retina surgeon’s AMD regimen at center of Medicare fraud case

Earlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.



Gary D. Novack, PhD

Latest:

Novel therapies abound in pipeline

The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.


Dr Zachary Bodnar

Latest:

Diagnosing and treating MacTel degenerative retinal disease

Idiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.


Margaret Wong, MD

Latest:

Scleral buckle technique using PPV, laser photocoagulation

Scleral buckles and vitrectomy are the two main procedures used today to treat retinal detachments, with many surgeons performing a combination of the two.


Dr Andrzej Grzybowski

Latest:

Assessing the impact of FLACS on surgical outcomes

FLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.


Dr Piotr Kanclerz

Latest:

Assessing the impact of FLACS on surgical outcomes

FLACS is related to an increase of anterior chamber prostaglandin and cytokines, resulting in intra-operative miosis. This can be prevented by pre-operative non-steroidal anti-inflammatory drug application. As a result of methodological problems, several studies on the association between femtosecond laser-assisted cataract surgery and cystoid macular oedema are inconclusive.


Lawrence P.L. IU

Latest:

Outer retinal layer thickness predicts visual acuity in diabetic macular oedema

Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.


Dr Peter Karth

Latest:

Diagnosing and treating MacTel degenerative retinal disease

Idiopathic macular telangiectasia (MacTel) is bilateral condition characterised by ectatic capillaries of the macula and atrophy of the neurosensory retina. Familiarity with the distinctive intraretinal cavitation on SD-OCT in type 2, the most common type, is key for correct diagnosis.


Ian Y.H. Wong

Latest:

Outer retinal layer thickness predicts visual acuity in diabetic macular oedema

Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.


OTE Staff Reports

Latest:

Prevent Blindness observes inherited retinal disease genetic testing week May 16-22

Prevent Blindness dedicates the third week of May to raising awareness of the benefit of genetic testing, variety of retinal diseases, and available resources.


Lisa Stewart

Latest:

2023: What awaits ophthalmology in the year ahead

As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.


Michelle Dalton, ELS

Latest:

Considering YAG vitreolysis for persistent vitreous floaters

Study evaluates the impact of surgical procedure on visual outcomes in patients


Joshua Mali, MD

Latest:

SNAPS Eye Shield: Creating the gold standard for postoperative ocular protection

Despite its status as an essential postoperative safety eye product and its utilization by every ocular surgeon with every ocular surgery, eye shield innovation has been neglected to date.



Ophthalmology Times Staff Reports

Latest:

OWL Leadership Summit 2023: Navigating ophthalmic leadership challenges and embracing diversity

The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.


Cheryl Guttman Krader, BS, Pharm

Latest:

Elucidating Alzheimer disease pathophysiology

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.


Lynda Enoch Charters
Lynda Charters

Latest:

Discovery of a common mechanistic defect and potential therapies for AMD and related macular dystrophies

A new study described the underlying defect responsible for development of AMD and related macular dystrophies (MDs).


Louise Gagnon

Latest:

Treating AMD and DME with faricimab: A therapy with lower treatment burden

According to physician, this therapeutic may prove to be a treatment option for these diseases.

© 2024 MJH Life Sciences

All rights reserved.